Cargando…
Recent developments of protein kinase inhibitors as potential AD therapeutics
Present Alzheimer’s disease (AD) therapies suffer from inefficient effects on AD symptoms like memory or cognition, especially in later states of the disease. Used acteylcholine esterase inhibitors or the NMDA receptor antagonist memantine address one target structure which is involved in a complex,...
Autores principales: | Tell, Volkmar, Hilgeroth, Andreas |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3832900/ https://www.ncbi.nlm.nih.gov/pubmed/24312003 http://dx.doi.org/10.3389/fncel.2013.00189 |
Ejemplares similares
-
Profiling tyrosine kinase inhibitors as AD therapeutics in a mouse model of AD
por: Lee, Hyun-ju, et al.
Publicado: (2023) -
Discovery of novel dual inhibitors of receptor tyrosine kinases EGFR and IGF-1R
por: Hempel, Cornelius, et al.
Publicado: (2017) -
MKK4 Inhibitors—Recent Development Status and Therapeutic Potential
por: Katzengruber, Leon, et al.
Publicado: (2023) -
Discovery of novel dual inhibitors of receptor tyrosine kinases EGFR and PDGFR-β related to anticancer drug resistance
por: Fischer, Tim, et al.
Publicado: (2017) -
Discovery of Novel Symmetrical 1,4-Dihydropyridines as Inhibitors of Multidrug-Resistant Protein (MRP4) Efflux Pump for Anticancer Therapy
por: Döring, Henry, et al.
Publicado: (2020)